Serum levels of low molecular weight advanced glycation end products in diabetic subjects
- 27 June 2003
- journal article
- website
- Published by Wiley in Diabetic Medicine
- Vol. 20 (7) , 575-579
- https://doi.org/10.1046/j.1464-5491.2003.00973.x
Abstract
Aims One of the principal theories of the development of diabetic complications proposes that increased levels of advanced glycation end products (AGE) are formed in diabetes by prolonged exposure of...Keywords
This publication has 31 references indexed in Scilit:
- Advanced glycation end-products: a reviewDiabetologia, 2001
- Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patientsHeart, 2001
- The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulationDiabetologia, 2000
- Accumulation of α-oxoaldehydes during oxidative stress: a role in cytotoxicityBiochemical Pharmacology, 1999
- The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinasDiabetologia, 1997
- The maillard or browning reaction in diabetesEye, 1993
- Advanced Glycosylation End Products in Patients with Diabetic NephropathyNew England Journal of Medicine, 1991
- Role of Oxidative Stress in Development of Complications in DiabetesDiabetes, 1991
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986